Compare CATO & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATO | IMA |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.0M | 66.3M |
| IPO Year | 1994 | N/A |
| Metric | CATO | IMA |
|---|---|---|
| Price | $3.19 | $6.01 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 72.9K | 14.2K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $653,812,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.87 | ★ N/A |
| Revenue Growth | ★ 0.62 | N/A |
| 52 Week Low | $2.59 | $3.94 |
| 52 Week High | $4.92 | $17.50 |
| Indicator | CATO | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 56.50 |
| Support Level | $2.80 | $5.86 |
| Resistance Level | $3.27 | $6.06 |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 15.58 | 71.83 |
The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.